+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Schizophrenia Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

  • ID: 4911468
  • Report
  • October 2019
  • Region: Global
  • 148 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • Allergan
  • AstraZeneca Plc
  • Eli Lilly & Co.
  • Maynepharma
  • Otsuka Holdings Co., Ltd
  • Pfizer Inc.
  • MORE
Schizophrenia Drugs Market - Scope of the Report

the report on the global schizophrenia drugs market studies the past as well as current growth trends and opportunities, and provides valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027. The report provides the overall market revenue of the global schizophrenia drugs market for the period of 2017 to 2027, with 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global schizophrenia drugs market for the forecast period of 2019 to 2027.

The report has been prepared after extensive research. Primary research involved bulk of the research efforts, wherein, analysts conducted interviews with market leaders and opinion makers. Extensive secondary research involves studying key players’ product literature, annual reports, press releases, and relevant documents to understand the schizophrenia drugs market.

Secondary research also includes Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of the top-down and bottom-up approach to study various phenomena in the schizophrenia drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the schizophrenia drugs market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the schizophrenia drugs market.

The report delves into the competitive landscape of the schizophrenia drugs market. Key players operating in the global schizophrenia drugs market are identified, and each one of them are profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT analysis are some of the attributes of the players in the global schizophrenia drugs market profiled in this report.

Key Questions Answered in the Global Schizophrenia Drugs Market Report
  • How does the development of schizophrenia drugs provide scope of growth in the schizophrenia drugs market?
  • How are alliances and partnerships between players widening the scope of new lines of treatment for schizophrenia?
  • What are the revenue share projections of key segments under various criteria in the global schizophrenia drugs market during the forecast period?
  • Which segment is likely to register leading revenue until the end of the forecast period?
  • How is the evolving healthcare system in developing countries of Asia Pacific making an impact on the overall schizophrenia drugs market?
Global Schizophrenia Drugs Market - Research Objectives and Research Approach

The comprehensive report on the schizophrenia drugs market begins with an overview of the said market, followed by the scope and objectives of this study. Following this, the report provides detailed explanation of the objectives behind this study, and healthcare compliances laid down by accredited agencies in the purview of the line of treatment of schizophrenia.

For reading comprehensibility, the report is compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of the key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global schizophrenia drugs market in terms of drug class, route of administration, and region. Key segments under each criteria are studied at length, and the market shares for each of them at the end of 2027 are provided herein. Such valuable insights enable market stakeholders in making informed business decisions for investment in the schizophrenia drugs market.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allergan
  • AstraZeneca Plc
  • Eli Lilly & Co.
  • Maynepharma
  • Otsuka Holdings Co., Ltd
  • Pfizer Inc.
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Schizophrenia Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Schizophrenia Drugs Introduction
4.1.2. Market Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Schizophrenia Drugs Market Analysis and Forecast, 2017–2027
4.4.1. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast

5. Key Insights
5.1. Pipeline Analysis: Schizophrenia Drugs
5.2. Value Chain Analysis
5.3. Global Schizophrenia Drugs Sales Analysis, 2017–2027

6. Global Schizophrenia Drugs Market Analysis and Forecast, by Drug Class
6.1. Introduction & Definitions
6.2. Key Findings / Developments
6.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
6.3.1. First Generation Drugs
6.3.2. Second Generation Drugs
6.3.3. Third Generation Drugs
6.4. Global Schizophrenia Drugs Market Attractiveness, by Drug Class

7. Global Schizophrenia Drugs Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definitions
7.2. Key Findings / Developments
7.3. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
7.3.1. Injectable
7.3.2. Oral
7.4. Global Schizophrenia Drugs Market Attractiveness, by Route of Administration

8. Global Schizophrenia Drugs Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Global Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Schizophrenia Drugs Market Attractiveness, by Region

9. North America Schizophrenia Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
9.2.1. First Generation Drugs
9.2.2. Second Generation Drugs
9.2.3. Third Generation Drugs
9.3. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
9.3.1. Injectable
9.3.2. Oral
9.4. North America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. North America Schizophrenia Drugs Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Route of Administration
9.5.3. By Country

10. Europe Schizophrenia Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
10.2.1. First Generation Drugs
10.2.2. Second Generation Drugs
10.2.3. Third Generation Drugs
10.3. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
10.3.1. Injectable
10.3.2. Oral
10.4. Europe Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Schizophrenia Drugs Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Route of Administration
10.5.3. By Country/Sub-region

11. Asia Pacific Schizophrenia Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
11.2.1. First Generation Drugs
11.2.2. Second Generation Drugs
11.2.3. Third Generation Drugs
11.3. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
11.3.1. Injectable
11.3.2. Oral
11.4. Asia Pacific Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Schizophrenia Drugs Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Route of Administration
11.5.3. By Country/Sub-region

12. Latin America Schizophrenia Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
12.2.1. First Generation Drugs
12.2.2. Second Generation Drugs
12.2.3. Third Generation Drugs
12.3. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
12.3.1. Injectable
12.3.2. Oral
12.4. Latin America Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Schizophrenia Drugs Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Route of Administration
12.5.3. By Country/Sub-region

13. Middle East & Africa Schizophrenia Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2017–2027
13.2.1. First Generation Drugs
13.2.2. Second Generation Drugs
13.2.3. Third Generation Drugs
13.3. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Route of Administration, 2017–2027
13.3.1. Injectable
13.3.2. Oral
13.4. Middle East & Africa Schizophrenia Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Schizophrenia Drugs Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Route of Administration
13.5.3. By Country/Sub-region

14. Competition Landscape
14.1. Global Schizophrenia Drugs Market Share Analysis, by Company (2018)
14.2. Company Profiles
14.2.1. Allergan
14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.1.2. Financial Overview
14.2.1.3. Product Portfolio
14.2.1.4. SWOT Analysis
14.2.1.5. Strategic Overview
14.2.2. Otsuka Holdings Co., Ltd
14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.2.2. Financial Overview
14.2.2.3. Product Portfolio
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Janssen Pharmaceutica (Johnson & Johnson)
14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.3.2. Financial Overview
14.2.3.3. Product Portfolio
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Pfizer Inc.
14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.4.2. Financial Overview
14.2.4.3. Product Portfolio
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Maynepharma
14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.5.2. Financial Overview
14.2.5.3. Product Portfolio
14.2.5.4. SWOT Analysis
14.2.5.5. Strategic Overview
14.2.6. Vanda Pharmaceuticals Inc.
14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.6.2. Financial Overview
14.2.6.3. Product Portfolio
14.2.6.4. SWOT Analysis
14.2.6.5. Strategic Overview
14.2.7. Sumitomo Dainippon Pharma
14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.7.2. Financial Overview
14.2.7.3. Product Portfolio
14.2.7.4. SWOT Analysis
14.2.7.5. Strategic Overview
14.2.8. Eli Lilly & Co.
14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.8.2. Financial Overview
14.2.8.3. Product Portfolio
14.2.8.4. SWOT Analysis
14.2.8.5. Strategic Overview
14.2.9. AstraZeneca Plc
14.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.2.9.2. Financial Overview
14.2.9.3. Product Portfolio
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Allergan
  • Otsuka Holdings Co., Ltd
  • Janssen Pharmaceutica (Johnson & Johnson)
  • Pfizer Inc.
  • Maynepharma
  • Vanda Pharmaceuticals Inc.
  • Sumitomo Dainippon Pharma
  • Eli Lilly & Co.
  • AstraZeneca Plc
Note: Product cover images may vary from those shown
Adroll
adroll